biochemically controlled with octreotide LAR: the LEAD study 2

[1]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[2]  P. Chanson,et al.  Expert consensus document: A consensus on the medical treatment of acromegaly , 2014, Nature Reviews Endocrinology.

[3]  A. Tabarin,et al.  Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial , 2013, The Journal of clinical endocrinology and metabolism.

[4]  L. Nachtigall,et al.  Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment , 2013, International journal of general medicine.

[5]  W. Woodmansee,et al.  Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry , 2013, Pituitary.

[6]  A. Burgess,et al.  Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study , 2012, Medical devices.

[7]  S. Ezzat,et al.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  P. Stewart,et al.  Mortality in patients with pituitary disease. , 2010, Endocrine reviews.

[9]  M. Molitch,et al.  Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly , 2009, Pituitary.

[10]  S. Melmed,et al.  Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension , 2009, Pituitary.

[11]  G. Arnaldi,et al.  Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly , 2009, Journal of endocrinological investigation.

[12]  R. Obach,et al.  Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects , 2009, Clinical pharmacokinetics.

[13]  X. Badia,et al.  Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. , 2009, The Journal of clinical endocrinology and metabolism.

[14]  G. Gamble,et al.  A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. , 2008, European journal of endocrinology.

[15]  S. Grottoli,et al.  Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study , 2007, Clinical endocrinology.

[16]  R. Astorga,et al.  Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial , 2006, Clinical endocrinology.

[17]  X. Badia,et al.  Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. , 2006, European journal of endocrinology.

[18]  P. Caron,et al.  Effectiveness and tolerability of 3‐year lanreotide Autogel® treatment in patients with acromegaly , 2006, Clinical endocrinology.

[19]  J. Wass,et al.  Systematic dose‐extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly , 2004, Clinical endocrinology.

[20]  J. Romijn,et al.  Sandostatin LAR in acromegaly: a 6‐week injection interval suppresses GH secretion as effectively as a 4‐week interval , 2003, Clinical endocrinology.